<div id="readability-page-1"><p>Shares of Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) were up 6.9% during mid-day trading on Wednesday . The stock traded as high as $1.72 and last traded at $1.71. Approximately 619,960 shares traded hands during trading, a decline of 4% from the average daily volume of 643,198 shares. The stock had previously closed at $1.60.</p><h2>Analysts Set New Price Targets</h2><p>A number of brokerages recently issued reports on IKT. Cantor Fitzgerald raised Inhibikase Therapeutics to a &#34;strong-buy&#34; rating in a research report on Thursday, December 11th. Zacks Research upgraded shares of Inhibikase Therapeutics to a &#34;hold&#34; rating in a research report on Tuesday, December 2nd. Wall Street Zen raised shares of Inhibikase Therapeutics to a &#34;sell&#34; rating in a report on Saturday, December 27th. Lifesci Capital upgraded shares of Inhibikase Therapeutics to a &#34;strong-buy&#34; rating in a research note on Monday, December 1st. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Inhibikase Therapeutics in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Strong Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, Inhibikase Therapeutics  has an average rating of &#34;Buy&#34;.</p><p><b>Check Out Our Latest Stock Report on Inhibikase Therapeutics</b></p><h2>Inhibikase Therapeutics Price Performance</h2><p>The stock has a market capitalization of $128.56 million, a P/E ratio of -4.38 and a beta of 0.84. The stock's 50 day simple moving average is $1.69. </p><p>Inhibikase Therapeutics (NASDAQ:IKT - Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.13) EPS for the quarter. </p><h2>About Inhibikase Therapeutics</h2> (Get Free Report)<p>Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Inhibikase Therapeutics</li><li>Is THIS the Next Big Money Rush?</li><li>Wall Street Legend Names #1 Stock of 2026 Live On-Camera</li><li>Trump’s Hand-Written Letter Will Shock his Haters</li><li>ISPC: From Small Cap to Life Sciences Market Disruptor!</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Inhibikase Therapeutics Right Now?</h2><p>Before you consider Inhibikase Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.</p><p>While Inhibikase Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LABD

SBIO

<p>Inhibikase Therapeutics (NASDAQ:IKT) shares rose 6.9% to $1.71 during mid-day trading. The stock's trading volume decreased by 4% compared to its average. Analysts have mixed ratings on the stock, with three giving it a "strong-buy," one a "hold," and one a "sell." The company, focused on developing therapeutics for Parkinson's Disease, reported a market cap of $128.56 million and a P/E ratio of -4.38. Despite the positive rating, it was not listed among top recommended stocks by analysts.</p>

Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9% - Time to Buy?